FASTDock:一个管道用于杂药物发现
Furyal Ahmed1, Charles L Brooks2
1Biophysics Program, University of Michigan, Ann Arbor, Michigan 48103, United States.
Journal of chemical information and modeling
|November 8, 2023
概括
研究人员开发了FASTDock,这是一个新的药物发现管道,用于识别异位和向它们的小分子. 这种方法有助于理解生物机制并开发新的治疗方法,而无需先前的连接物信息.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 在生物过程和人类疾病中,体调节至关重要,这使得它成为治疗开发的关键目标.
- 鉴定全位和合适的小分子调节器在药物发现中存在重大挑战,因为缺乏先前的配体信息.
研究的目的:
- 介绍FASTDock,一个新的计算管道,旨在发现可连接的全位.
- 为了识别能够准这些新发现的全位的小分子,而不依赖于现有的配体数据.
主要方法:
- 开发一个名为FASTDock的新药发现管道.
- 实施分层选策略,分析大量潜在连接体的数据库.
- 发现可结合的全位和相应的小分子结合剂.
主要成果:
- FASTDock成功地识别了受体上的潜在的全结合部位.
- 管道可以发现有效地准这些已识别的全位的小分子.
- 证明了在没有对目标部位的配体的先前知识的情况下进行的能力.
结论:
- FASTDock提供了一种新的方法来克服所有菌性药物发现的局限性.
- 这条管道有助于识别新型全性标和化合物.
- 能够为广的化学空间进行高通量选,加速治疗开发.
相关概念视频
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Cooperative Allosteric Transitions
2.3K
2.3K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Allosteric Regulation
58.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.0K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K


